Biotech Is On The Mend

After finding itself among the most oversold sectors last year, biotech is having its best start to a year since 2012 – a rally fueled by takeover speculation and some promising drug trial data presentations at the recent J.P. Morgan Health Care Conference. CLICK HERE.